Lilly breaks ground on $3.5 billion Pennsylvania site for obesity drugs

Eli Lilly broke ground on a $3.5 billion manufacturing facility in Lehigh Valley, Pennsylvania, to produce injectable obesity medicines including retatrutide. The site will create 850 high-wage jobs and 2,000 construction jobs, with operations expected by 2031. It is part of Lilly's $50 billion U.S. expansion across 10 sites since 2020.